Digitisation | August 11, 2021
Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
The aim is to create new genomics solutions that could combat cancer and advance market access
The aim is to create new genomics solutions that could combat cancer and advance market access
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
The drug is indicated for mild and transient episodes of heart block
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The goal for the project is the identification and optimization of anti-viral compounds.
Filing for WHO Emergency Use Authorisation this month
Subscribe To Our Newsletter & Stay Updated
